98%
921
2 minutes
20
In the field of chronic inflammatory rheumatism, while neutrophil extracellular traps (NETs) have been recognized as contributors to the pathogenesis of rheumatoid arthritis (RA), the underlying mechanism of the abnormal interaction between NETs and bone marrow mesenchymal stem cells (BMSCs) has remained unclear. Our study made several key findings. Firstly, we discovered that the osteogenic differentiation ability of BMSCs in RA patients was reduced. Additionally, we found that the increased production of NETs in RA patients impaired bone formation by weakening the osteogenic capacity of BMSCs. Specifically, NETs activated the NF-κB pathway in BMSCs, suppressing the expression of bone morphogenetic protein 2 (BMP2) and thus inhibiting osteogenesis, which could be counteracted by an NF - κB inhibitor. Moreover, NETs promoted BMSCs to secrete interleukin-8 (IL-8), attracting more neutrophils into the bone marrow. These findings highlight the role of NETs-induced activation of the p65/NF-κB pathway in inhibiting BMSC osteogenesis in RA and suggest that targeting p65 may be a potential therapeutic strategy for RA.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bone.2025.117533 | DOI Listing |
Rheumatology (Oxford)
September 2025
Department of Molecular Targeted Therapeutics, University of Occupational and Environmental Health, Kitakyushu, Japan, Japan.
Eur J Case Rep Intern Med
August 2025
Internal Medicine, University of California, Riverside School of Medicine, Riverside, USA.
Introduction: Pulmonary embolism (PE) is a life-threatening condition with well-defined management strategies; however, the presence of a clot-in-transit (CIT)-a mobile thrombus within the right heart-introduces a uniquely high-risk scenario associated with a significantly elevated mortality rate. While several therapeutic approaches are available-including anticoagulation, systemic thrombolysis, surgical embolectomy, and catheter-directed therapies-there is no established consensus on a superior treatment modality. Catheter-based mechanical thrombectomy has emerged as a promising, minimally invasive alternative that mitigates the bleeding risks of systemic thrombolysis and the invasiveness of surgery.
View Article and Find Full Text PDFEur J Case Rep Intern Med
August 2025
Dermatology Department, Ain Shams University Hospital, Cairo, Egypt.
Background: Dissecting cellulitis of the scalp (DCS) is a rare, chronic neutrophilic dermatosis that is often refractory to conventional therapies.
Case Report: We present a 29-year-old male with treatment-resistant DCS who achieved rapid and sustained remission following off-label use of tofacitinib, a Janus kinase (JAK) inhibitor. Previous therapies, including antibiotics, corticosteroids, and isotretinoin, had failed.
Ned Tijdschr Tandheelkd
September 2025
The Department of Oral and Maxillofacial Surgery, University Medical Center Groningen (UMCG), The Netherlands.
Systemic auto-immune diseases are relatively common. This article describes the oral manifestations of disorders that might be seen in patients with the most prevalent auto-immune diseases, specifically rheumatoid arthritis, systemic lupus erythematosus and Sjögren's disease. The article gives guidelines for dentists and other carers within the oral care system for this category of patients.
View Article and Find Full Text PDFEur J Clin Pharmacol
September 2025
Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Objective: This research aimed at evaluating the effectiveness and safety of nitazoxanide and escitalopram as adjuvant therapies in patients with rheumatoid arthritis (RA).
Methods: In this randomized controlled parallel study, 90 patients with active RA were randomized into three groups; group 1 (control group; n = 30) which received traditional therapy, group 2 (Nitazoxanide group; n = 30) which received traditional therapy plus 1 gm/day oral nitazoxanide, and group 3 (Escitalopram group; n = 30) which received traditional therapy plus 10 mg/day oral escitalopram for three months. At baseline and 3 months after treatment, clinical and functional assessments were done through the 28-joint count disease activity score using C-reactive protein (DAS28-CRP), the health assessment questionnaire-disability index (HAQ-DI), and the patient's global assessment (PGA).